EIT Health
VC Fund
Munich, Germany
EIT Health is a VC fund in Munich focused on Health Care and Medical Device. EIT Health promotes entrepreneurship and innovates in healthy living and active ageing, providing Europe with new opportunities and resources. It enables citizens to lead healthier and more productive lives by delivering products, services and concepts that improve quality of life and contribute to the sustainability of healthcare across Europe.
- Total investments:
- 106
- Last investment:
- Lead investor:
- 59%
Last updated:
For AI agents: llms.txt
Industries EIT Health invests in
Stages EIT Health invests in
Countries EIT Health invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 10 contacts → | |||
Round size
- Seed
- $220k–$1.4M
- Grant
- $27k–$1.6M
- Pre-Seed
- $45k–$1.7M
Investment Focus
Industry
- Health Care 66 (62%)
- Medical Device 38 (36%)
- Medical 32 (30%)
- Biotechnology 28 (26%)
- Software 19 (18%)
Stage
- Grant 58 (55%)
- Pre-Seed 23 (22%)
- Seed 6 (6%)
- Non-equity Assistance 4 (4%)
- Series A 3 (3%)
Country
- United Kingdom 16 (15%)
- Spain 14 (13%)
- Ireland 10 (9%)
- Switzerland 10 (9%)
- Germany 8 (8%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Joy Cuerten
Head of Accelerator
|
Head of Accelerator | Total investments: 0 | Find email | |
Marc Butterly
Business Creation Lead (Ireland & UK)
|
Business Creation Lead (Ireland & UK) | Total investments: 0 | Find email | |
Bernald Leone
Mentor
|
Mentor | Total investments: 0 | Find email | |
Dawn Bell
Executive Council Member, Gold Track Program
|
Executive Council Member, Gold Track Program | Total investments: 0 | Find email | |
Helena Torras
Independent Expert Evaluator & Jury (occasional)
|
Independent Expert Evaluator & Jury (occasional) | Total investments: 2 | Find email | |
| See all 10 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Trak is a software tool for healthcare professional to provide AI-based tele-rehabilitation services like physiotherapy and others. | Grant / Feb 01, 2024 | ||
| At Noah Labs, we develop technology that can hear cardiovascular diseases from patients voice recorded with a smartphone. We enable patients to live healthier, longer lives. | $1.7M / Grant / Jan 01, 2024 | ||
| Idoven has developed the world’s first AI cardiologist -Willem- that augments both a cardiologist’s and non-cardiology expert clinician’s ability to identify, triage and diagnose patients at scale through APIs. The company counts clients such as AstraZeneca, Abbott, Novartis, GE Healthcare, FIFPRO, Google, Santander and Real Madrid Foundation.Idoven is backed by top-tier investors and business angels including Insight Partners, Northzone and Wayra (Telefónica), Iker Casillas, Pau Gasol, the Accel Starters program, EIC Accelerator, Horizon 2020, ERC and EIT Health. The company has been awarded with numerous distinctions for its AI technology in Europe and the US, including the the European Seal of Excellence 3x from the European Commission, granted by Horizon 2020, European Research Council ERC 2x (RIA) Europe’s most prestigious research grant, supporting excellent researchers in carrying out ground-breaking, high-risk, high-gain, frontier research projects, EIC Accelerator, and EIT Health. Idoven was ranked #1 Spanish HealthTech company in 2020 by NEOTEC. Idoven has been Google for Startups Resident at Google Campus Madrid and part of the Google for Startups Global Alumni Program. The company has won the prize Emprendedor XXI from CaixaBank, the Healthy Longevity Catalyst Award from the U.S. National Academy of Medicine, and has been awarded at South Summit 2021 as the Most Disruptive Startup, and Best Health and Wellbeing Startup. Selected by CB Insights as one of the top 150 global companies in Digital Health for 2022, and top 50 global companies in Digital Health for 2023. Idoven was recognized by TIME Magazine as one of the World's Top HealthTech Companies of 2025. | $1.6M / Grant / Jul 31, 2023 | ||
| eBreathie is a pioneering digital health startup offering an integrated asthma management solution. Our system comprises a smart inhaler (a medical device) that not only tracks WHEN patients take their medication but also HOW they do it, creating a detailed inhalation profile for each use. Paired with a user-friendly mobile app for patients and acomprehensive patient management platform for doctors, we provide real-time feedback on inhalation efficacy, ensuring patients and healthcare professionals have the insights needed for optimal asthma management. Leveraging IoT and AI, our goal is to reduce emergency visits, asthma attacks, and hospitalizations while ensuring effective inhalation techniques and optimal patient care. | $27.9K / Grant / Jul 12, 2023 | ||
| NIB Biotec is an innovative company specializing in the development of innovative in vitro diagnostic solutions for prostate cancer. The company focuses on biomarker-based technologies, particularly leveraging patented urinary biomarkers to create rapid and non-invasive diagnostic tests. Its mission is to improve early detection and clinicaldecision-making in urology through accessible, high-performance diagnostic tools. NIB Biotec collaborates with research institutions and clinical partners to integrate its solutions into future diagnostic pathways, aiming to transform prostate cancer screening and monitoring. | $1.2M / Seed / Oct 23, 2022 | ||
| Ochre Bio develops genomic medicines to rejuvenate donors' livers before transplant, so that everyone who needs a new liver gets one. They use genomics to find and shut down over-active genes driving disease and then go directly to testing therapies in discarded donor livers that keep alive outside of the body.Ochre Bio is within the heartof Oxford’s biotech innovation hub. Their scientific roots can be traced back to over 15 years leading liver genomics research and experience in bringing advanced therapies to market. | $30M / Series A / Oct 10, 2022 | ||
| Inspired by my mother's loss to preventable kidney failure, I founded Fourth Vital, an Oakland-based Medtech startup. We craft AI-driven early-warning systems for chronic kidney disease (CKD), aiming to save over $125 billion annually in U.S. hospital costs and dramatically improve patient outcomes. Our SaaS solution predicts CKD much earlierthan current methods. We've launched in Canada and have a global waiting list of clinics. | Non-equity Assistance / Sep 01, 2022 | ||
| Nanordica Medical is an Estonian medical technology company providing the first-line treatment for chronic wounds based on unique patented nanotechnology, a synergy of copper and silver in nanofibers that remove infection and support wound healing.Nanordica Medical launched a veterinary product Ravimus Vet for animal wounds(https://nanordica.com/ravimus.html) and is developing a first-in-class wound dressing for human hard-to-heal wounds like diabetic foot ulcers. They recently completed a clinical trial showing consistently better results in nearly all efficacy parameters observed among the patients treated with the Nanordica wound dressing than those treated with the commercially available silver ions-based active dressing. | $26.8K / Grant / May 31, 2022 | ||
| ZiO Health is a biotechnology company that has developed proprietary pocket-sized technology, bringing laboratory testing to the point-of-care to improve patient outcomes. Using ZiO Health's proprietary biosensor technology & machine learning algorithms we combine real-time results with the patients unique profile to enhance patient care. | Grant / May 02, 2022 | ||
| OptiChroniX is a Swiss Digital Therapeutics company dedicated to improving brain health early. We strive to optimize lifestyle and make medicine smart, so as to improve clinical outcomes, quality of life, cost-effectiveness, and budget impact of clinical treatment.At OptiChroniX, we develop digital health interventions at the intersection ofbiomedical, behavioral, computing, and engineering research, deployed on smartphones to personalize and track a patient’s health progress by collecting data from other wearables and nearables. The informed choices offered aim to provide tailored coaching in order to improve health literacy and medication adherence and to positively impact modifiable risk factors primarily responsible for the cognitive decline in patients affected by Alzheimer’s disease and associated co-morbidities. | $11K / Pre-Seed / Mar 15, 2022 | ||
| See all 106 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does EIT Health invest in?
EIT Health invests primarily in Health Care, Medical Device and Medical startups, most often at Grant and Pre-Seed stage. Most of the 106 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is EIT Health's check size?
EIT Health typically joins rounds of $220k–$1.4M at Seed, $27k–$1.6M at Grant and $45k–$1.7M at Pre-Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds EIT Health participates in.
How do I contact EIT Health?
Public channels for EIT Health include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at EIT Health?
The team at EIT Health includes Joy Cuerten (Head of Accelerator), Marc Butterly (Business Creation Lead (Ireland & UK)) and Bernald Leone (Mentor), among 10 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
